| Standard dosage | 5 mg daily starting dose, titrate to 10 mg twice a day |
| Contraindications | use with caution in patients with severe hepatic or renal impairment |
| Main drug interactions | no major drug interactions |
| Main side effects | generally well tolerated, rare insomnia, confusion, dizziness, agitation |
| Cost | unclear, Forest Pharmaceuticals has announced discontinuation of Namenda on August 15, 2014 in anticipation of Namenda extended release formulation. Namenda loses patent protection on April 11, 2015. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.